-
1
-
-
0029759541
-
Annual hazard rates of recurrence for breast cancer after primary therapy
-
Saphner T, Tormey DC, Gray R: Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol 14:2738-2746, 1996
-
(1996)
J Clin Oncol
, vol.14
, pp. 2738-2746
-
-
Saphner, T.1
Tormey, D.C.2
Gray, R.3
-
2
-
-
0032537396
-
Tamoxifen for early breast cancer: An overview of the randomised trials - Early Breast Cancer Trialists' Collaborative Group
-
[No authors listed]: Tamoxifen for early breast cancer: An overview of the randomised trials - Early Breast Cancer Trialists' Collaborative Group. Lancet 351:1451-1467, 1998
-
(1998)
Lancet
, vol.351
, pp. 1451-1467
-
-
-
3
-
-
34548144485
-
Tamoxifen for early breast cancer
-
Early Breast Cancer Trialists' Collaborative Group: Tamoxifen for early breast cancer. Cochrane Database Syst Rev 1:CD000486, 2001
-
(2001)
Cochrane Database Syst Rev
, vol.1
-
-
-
4
-
-
33646789495
-
Preventing relapse beyond 5 years: The MA.17 extended adjuvant trial
-
Goss PE: Preventing relapse beyond 5 years: The MA.17 extended adjuvant trial. Semin Oncol 33:S8-S12, 2006
-
(2006)
Semin Oncol
, vol.33
, pp. S8-S12
-
-
Goss, P.E.1
-
5
-
-
51049084866
-
Residual risk of breast cancer recurrence 5 years after adjuvant therapy
-
Brewster AM, Hortobagyi GN, Broglio KR, et al: Residual risk of breast cancer recurrence 5 years after adjuvant therapy. J Natl Cancer Inst 100:1179-1183, 2008
-
(2008)
J Natl Cancer Inst
, vol.100
, pp. 1179-1183
-
-
Brewster, A.M.1
Hortobagyi, G.N.2
Broglio, K.R.3
-
6
-
-
84866544308
-
Molecular tumor characteristics influence adjuvant endocrine treatment outcome
-
Bianchini G, Pusztai L, Iwamoto T, et al: Molecular tumor characteristics influence adjuvant endocrine treatment outcome. Cancer Res 71:S1-S7, 2011
-
(2011)
Cancer Res
, vol.71
, pp. S1-S7
-
-
Bianchini, G.1
Pusztai, L.2
Iwamoto, T.3
-
7
-
-
84881257906
-
Breast cancer index identifies early-stage estrogen receptor-positive breast cancer patients at risk for early- and late-distant recurrence
-
Zhang Y, Schnabel CA, Schroeder BE, et al: Breast cancer index identifies early-stage estrogen receptor-positive breast cancer patients at risk for early- and late-distant recurrence. Clin Cancer Res 19:4196-4205, 2013
-
(2013)
Clin Cancer Res
, vol.19
, pp. 4196-4205
-
-
Zhang, Y.1
Schnabel, C.A.2
Schroeder, B.E.3
-
8
-
-
84883456580
-
Comparative performance of Breast Cancer Index (BCI) vs. Oncotype Dx and IHC4 in the prediction of late recurrence in hormonal receptor-positive lymph node-negative breast cancer patients: A TransATAC Study
-
Sgroi DC, Sestak I, Cuzick J, et al: Comparative performance of Breast Cancer Index (BCI) vs. Oncotype Dx and IHC4 in the prediction of late recurrence in hormonal receptor-positive lymph node-negative breast cancer patients: A TransATAC Study. Cancer Res 72:S1-S9, 2012
-
(2012)
Cancer Res
, vol.72
, pp. S1-S9
-
-
Sgroi, D.C.1
Sestak, I.2
Cuzick, J.3
-
9
-
-
84890426904
-
The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2- breast cancer patients
-
Dubsky P, Brase JC, Jakesz R, et al: The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2- breast cancer patients. Br J Cancer 109:2959-2964, 2013
-
(2013)
Br J Cancer
, vol.109
, pp. 2959-2964
-
-
Dubsky, P.1
Brase, J.C.2
Jakesz, R.3
-
10
-
-
62449131093
-
Supervised risk predictor of breast cancer based on intrinsic subtypes
-
Parker JS, Mullins M, Cheang MC, et al: Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 27:1160-1167, 2009
-
(2009)
J Clin Oncol
, vol.27
, pp. 1160-1167
-
-
Parker, J.S.1
Mullins, M.2
Cheang, M.C.3
-
11
-
-
78049453780
-
A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer
-
Nielsen TO, Parker JS, Leung S, et al: A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer. Clin Cancer Res 16:5222-5232, 2010
-
(2010)
Clin Cancer Res
, vol.16
, pp. 5222-5232
-
-
Nielsen, T.O.1
Parker, J.S.2
Leung, S.3
-
12
-
-
84884762173
-
Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy
-
Dowsett M, Sestak I, Lopez-Knowles E, et al: Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy. J Clin Oncol 31:2783-2790, 2013
-
(2013)
J Clin Oncol
, vol.31
, pp. 2783-2790
-
-
Dowsett, M.1
Sestak, I.2
Lopez-Knowles, E.3
-
13
-
-
84893424611
-
Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: Using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone
-
Gnant M, Filipits M, Greil R, et al: Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: Using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone. Ann Oncol 25:339-345, 2014
-
(2014)
Ann Oncol
, vol.25
, pp. 339-345
-
-
Gnant, M.1
Filipits, M.2
Greil, R.3
-
14
-
-
37449028688
-
Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial
-
Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists' Group, Forbes JF, Cuzick J, et al: Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 9:45-53, 2008
-
(2008)
Lancet Oncol
, vol.9
, pp. 45-53
-
-
Forbes, J.F.1
Cuzick, J.2
-
15
-
-
41949104971
-
Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial
-
Dowsett M, Allred C, Knox J, et al: Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial. J Clin Oncol 26:1059-1065, 2008
-
(2008)
J Clin Oncol
, vol.26
, pp. 1059-1065
-
-
Dowsett, M.1
Allred, C.2
Knox, J.3
-
16
-
-
84857508799
-
Tamoxifen and anastrozole as a sequencing strategy: A randomized controlled trial in postmenopausal patients with endocrine-responsive early breast cancer from the Austrian Breast and Colorectal Cancer Study Group
-
Dubsky PC, Jakesz R, Mlineritsch B, et al: Tamoxifen and anastrozole as a sequencing strategy: A randomized controlled trial in postmenopausal patients with endocrine-responsive early breast cancer from the Austrian Breast and Colorectal Cancer Study Group. J Clin Oncol 30:722-728, 2012
-
(2012)
J Clin Oncol
, vol.30
, pp. 722-728
-
-
Dubsky, P.C.1
Jakesz, R.2
Mlineritsch, B.3
-
17
-
-
81155133281
-
Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer
-
Cuzick J, Dowsett M, Pineda S, et al: Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer. J Clin Oncol 29:4273-4278, 2011
-
(2011)
J Clin Oncol
, vol.29
, pp. 4273-4278
-
-
Cuzick, J.1
Dowsett, M.2
Pineda, S.3
-
18
-
-
84924998521
-
Comparison of PAM50 risk of recurrence (ROR) score with OncotypeDx and IHC4 for predicting residual risk of RFS and distant-(D)RFS after endocrine therapy: A TransATAC study
-
Presented at the
-
th Annual CTRC-AACR San Antonio Breast Cancer Symposium, San Antonio, TX, December 6-10, 2011
-
th Annual CTRC-AACR San Antonio Breast Cancer Symposium, San Antonio, TX, December 6-10, 2011
-
-
Dowsett, M.1
Lopez-Knowles, E.2
Sidhu, K.3
-
19
-
-
38849091997
-
Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond
-
Pencina MJ, D'Agostino RB Sr, D'Agostino RB Jr, et al: Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond. Stat Med 27:157-172, 2008
-
(2008)
Stat Med
, vol.27
, pp. 157-172
-
-
Pencina, M.J.1
D'Agostino, R.B.2
D'Agostino, R.B.3
-
20
-
-
78649477601
-
Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers
-
Pencina MJ, D'Agostino RB Sr, Steyerberg EW: Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat Med 30:11-21, 2011
-
(2011)
Stat Med
, vol.30
, pp. 11-21
-
-
Pencina, M.J.1
D'Agostino, R.B.2
Steyerberg, E.W.3
-
21
-
-
78649603622
-
Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial
-
Cuzick J, Sestak I, Baum M, et al: Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol 11:1135-1141, 2010
-
(2010)
Lancet Oncol
, vol.11
, pp. 1135-1141
-
-
Cuzick, J.1
Sestak, I.2
Baum, M.3
-
22
-
-
84883449158
-
Clinical validation of the PAM50 risk of recurrence (ROR) score for predicting residual risk of distant-recurrence (DR) after endocrine therapy in postmenopausal women with ER+ early breast cancer (EBC): An ABCSG study
-
abstr P2-10-02
-
Gnant M, Filipits M, Mlineritsch B, et al: Clinical validation of the PAM50 risk of recurrence (ROR) score for predicting residual risk of distant-recurrence (DR) after endocrine therapy in postmenopausal women with ER+ early breast cancer (EBC): An ABCSG study. Cancer Res 72, 2012 (suppl 3: abstr P2-10-02)
-
(2012)
Cancer Res
, vol.72
-
-
Gnant, M.1
Filipits, M.2
Mlineritsch, B.3
-
23
-
-
80052641331
-
Biologic markers determine both the risk and the timing of recurrence in breast cancer
-
Esserman LJ, Moore DH, Tsing PJ, et al: Biologic markers determine both the risk and the timing of recurrence in breast cancer. Breast Cancer Res Treat 129:607-616, 2011
-
(2011)
Breast Cancer Res Treat
, vol.129
, pp. 607-616
-
-
Esserman, L.J.1
Moore, D.H.2
Tsing, P.J.3
-
24
-
-
24744450378
-
Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: Updated findings from NCIC CTG MA.17
-
Goss PE, Ingle JN, Martino S, et al: Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: Updated findings from NCIC CTG MA.17. J Natl Cancer Inst 97:1262-1271, 2005
-
(2005)
J Natl Cancer Inst
, vol.97
, pp. 1262-1271
-
-
Goss, P.E.1
Ingle, J.N.2
Martino, S.3
-
25
-
-
84873868973
-
Impact of premenopausal status at breast cancer diagnosis in women entered on the placebo-controlled NCIC CTG MA17 trial of extended adjuvant letrozole
-
Goss PE, Ingle JN, Martino S, et al: Impact of premenopausal status at breast cancer diagnosis in women entered on the placebo-controlled NCIC CTG MA17 trial of extended adjuvant letrozole. Ann Oncol 24:355-361, 2013
-
(2013)
Ann Oncol
, vol.24
, pp. 355-361
-
-
Goss, P.E.1
Ingle, J.N.2
Martino, S.3
-
26
-
-
42949104549
-
Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: Intention-to-treat analysis of the National Surgical Adjuvant Breast and Bowel Project B-33 trial
-
Mamounas EP, Jeong JH, Wickerham DL, et al: Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: Intention-to-treat analysis of the National Surgical Adjuvant Breast and Bowel Project B-33 trial. J Clin Oncol 26:1965-1971, 2008
-
(2008)
J Clin Oncol
, vol.26
, pp. 1965-1971
-
-
Mamounas, E.P.1
Jeong, J.H.2
Wickerham, D.L.3
|